Alethia Biotherapeutics Inc. has entered into a licensing agreement with Canada's National Research Council Biotechnology Research Institute (NRC-BRI) for the worldwide therapeutic and diagnostic rights to Clusterin-specific antibodies. (BioWorld Today) Read More
